KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 3,880,000 shares, a drop of 5.4% from the August 15th total of 4,100,000 shares. Based on an average daily volume of 203,400 shares, the days-to-cover ratio is presently 19.1 days.
Insider Transactions at KalVista Pharmaceuticals
In related news, CFO Benjamin L. Palleiko sold 13,067 shares of the firm's stock in a transaction on Friday, August 18th. The shares were sold at an average price of $10.73, for a total transaction of $140,208.91. Following the sale, the chief financial officer now directly owns 95,254 shares in the company, valued at $1,022,075.42. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Benjamin L. Palleiko sold 13,067 shares of the business's stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $10.73, for a total transaction of $140,208.91. Following the transaction, the chief financial officer now directly owns 95,254 shares in the company, valued at approximately $1,022,075.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Albert Cha sold 18,000 shares of the business's stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $10.50, for a total transaction of $189,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 53,963 shares of company stock valued at $574,883 over the last three months. 12.30% of the stock is currently owned by corporate insiders.
Institutional Trading of KalVista Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the business. Jefferies Financial Group Inc. purchased a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $8,112,000. VR Adviser LLC acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $19,717,000. Opaleye Management Inc. acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $6,241,000. Connor Clark & Lunn Investment Management Ltd. increased its position in KalVista Pharmaceuticals by 6.9% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 99,871 shares of the specialty pharmaceutical company's stock worth $785,000 after buying an additional 6,458 shares during the period. Finally, Boxer Capital LLC acquired a new position in KalVista Pharmaceuticals during the first quarter worth approximately $12,969,000.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, August 22nd. HC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, September 8th.
View Our Latest Analysis on KalVista Pharmaceuticals
KalVista Pharmaceuticals Stock Performance
Shares of KALV opened at $9.80 on Tuesday. The company's fifty day moving average is $10.39 and its 200 day moving average is $9.35. KalVista Pharmaceuticals has a fifty-two week low of $4.12 and a fifty-two week high of $15.22. The stock has a market capitalization of $337.12 million, a PE ratio of -3.10 and a beta of 0.94.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, September 7th. The specialty pharmaceutical company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.12. As a group, research analysts forecast that KalVista Pharmaceuticals will post -2.83 earnings per share for the current year.
About KalVista Pharmaceuticals
(Get Free Report
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report